<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489486</url>
  </required_header>
  <id_info>
    <org_study_id>MET-REPAIR PRESEPSIN</org_study_id>
    <nct_id>NCT03489486</nct_id>
  </id_info>
  <brief_title>Presepsin (sCD14-ST) for Prediction of Perioperative Risk - MET-REPAIR Nested Cohort Study</brief_title>
  <acronym>P^3-MET-REPAIR</acronym>
  <official_title>MET: REevaluation for Perioperative cArdIac Risk (MET-REPAIR): a Prospective, Multi-centre Cohort Observational Study- Presepsin (sCD14-ST) for Perioperative Risk Prediction Nested Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Society of Anaesthesiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre international prospective cohort study designed to evaluate whether preoperative
      presepsin (sCD14-ST) is associated with the composite endpoint: all-cause mortality and major
      adverse cardiovascular or cerebrovascular events (MACCE) after elevated risk non-cardiac
      surgery. If so:

        1. What is the optimal cut-off for presepsin to predict the composite endpoint all-cause
           mortality and MACCE?

        2. Does the calculated optimal cut-off improve prediction of the composite endpoint
           all-cause mortality and MACCE when added to clinical data and established biomarkers?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major non-cardiac surgery is still associated with relevant cardiovascular mortality and
      morbidity. In Europe, in-hospital mortality exceeded 7% in patients with coronary artery
      disease and in those with congestive heart failure. Within 30 days of non-cardiac surgery
      procedures, 8% of patients will suffer a major cardiovascular event.

      Immunological processes, increased recruitment and infiltration of innate and adaptive immune
      cells into atherosclerotic lesions, have been shown to drive perioperative atherosclerotic
      lesion progression and plaque destabilization and are thought to promote plaque rupture. When
      classical monocytes are activated to inflammatory non-classical monocytes, the membrane-bound
      cell surface protein CD14 is released into circulation. In plasma, soluble CD14 (sCD14) is
      cleaved by lysosomal proteases. The N-terminal 13kDa fragment constitutes sCD14 subtype
      (sCD14-ST), also called presepsin. Presepsin has been established as a marker for early
      identification of patients with systemic infections. Recently, presepsin has been proposed as
      a biomarker for preoperative risk prediction in cardiac surgery. Our preliminary results in a
      limited number of patients suggest that presepsin is associated with major adverse
      cardiovascular and cerebrovascular events after non-cardiac surgery as well with all-cause
      mortality. Presepsin might have a test characteristic superior to conventional risk
      assessment on the basis of the revised cardiac risk index (RCRI), high-sensitivity cardiac
      Troponin-T (hs-cTnT) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP).

      Preoperative presepsin quantification might help to identify non-cardiac surgery patients
      prone to experience perioperative major adverse cardiovascular and cerebrovascular events.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of all-cause mortality and Major Adverse Cardiovascular or Cerebrovascular Events</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>Number of Patients with Composite of all-cause mortality and Major Adverse Cardiovascular or Cerebrovascular Event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that die of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiovascular or Cerebrovascular Events</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with a Major Adverse Cardiovascular or Cerebrovascular Event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal cardiac arrest</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with non-fatal cardiac arrest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congestive heart failure requiring transfer to a higher unit of care or prolonging stay on ICU/intermediate care (≥24h)</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with congestive heart failure requiring transfer to a higher unit of care or prolonging stay on ICU/intermediate care (≥24h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that die of a cardiovascular cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital all-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients that die in hospital of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications ≥ 3 in Clavien Dindo Classification</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>Number of patients with ≥ 3 complications in Clavien Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>Number of days participants stayed in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>Number of days participants stayed in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial injury after non-cardiac surgery (MINS)</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <description>Number of Patients with MINS</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1695</enrollment>
  <condition>Non Cardiac Surgery</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients undergoing elective, elevated-risk noncardiac surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Enrollment in MET-REPAIR (NCT03016936)

          -  Signed written informed consent

        No exclusion criteria

        I
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Larmann, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Univeristy Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Larmann, MD/PhD</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>39447</phone_ext>
    <email>jan.larmann@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florian Espeter, MD</last_name>
    <phone>+49 6221 56</phone>
    <phone_ext>36772</phone_ext>
    <email>florian.espeter@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Anaesthesiology, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, Vallet B, Vincent JL, Hoeft A, Rhodes A; European Surgical Outcomes Study (EuSOS) group for the Trials groups of the European Society of Intensive Care Medicine and the European Society of Anaesthesiology. Mortality after surgery in Europe: a 7 day cohort study. Lancet. 2012 Sep 22;380(9847):1059-65. doi: 10.1016/S0140-6736(12)61148-9.</citation>
    <PMID>22998715</PMID>
  </reference>
  <reference>
    <citation>Devereaux PJ, Mrkobrada M, Sessler DI, Leslie K, Alonso-Coello P, Kurz A, Villar JC, Sigamani A, Biccard BM, Meyhoff CS, Parlow JL, Guyatt G, Robinson A, Garg AX, Rodseth RN, Botto F, Lurati Buse G, Xavier D, Chan MT, Tiboni M, Cook D, Kumar PA, Forget P, Malaga G, Fleischmann E, Amir M, Eikelboom J, Mizera R, Torres D, Wang CY, VanHelder T, Paniagua P, Berwanger O, Srinathan S, Graham M, Pasin L, Le Manach Y, Gao P, Pogue J, Whitlock R, Lamy A, Kearon C, Baigent C, Chow C, Pettit S, Chrolavicius S, Yusuf S; POISE-2 Investigators. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014 Apr 17;370(16):1494-503. doi: 10.1056/NEJMoa1401105. Epub 2014 Mar 31.</citation>
    <PMID>24679062</PMID>
  </reference>
  <reference>
    <citation>Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, De Hert S, Ford I, Gonzalez Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, Kjeldsen KP, Longrois D, Luescher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Uva MS, Voudris V, Funck-Brentano C; Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014 Oct;31(10):517-73. doi: 10.1097/EJA.0000000000000150. Review.</citation>
    <PMID>25127426</PMID>
  </reference>
  <reference>
    <citation>Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeysundera DN; American College of Cardiology; American Heart Association. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014 Dec 9;64(22):e77-137. doi: 10.1016/j.jacc.2014.07.944. Epub 2014 Aug 1.</citation>
    <PMID>25091544</PMID>
  </reference>
  <reference>
    <citation>Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999 Sep 7;100(10):1043-9.</citation>
    <PMID>10477528</PMID>
  </reference>
  <reference>
    <citation>Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang X, Miller WJ, Esterbrooks DJ, Hunter CB, Pipinos II, Johanning JM, Lynch TG, Forse RA, Mohiuddin SM, Mooss AN. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation. 2011 Jul 26;124(4):381-7. doi: 10.1161/CIRCULATIONAHA.110.015701. Epub 2011 Jul 5.</citation>
    <PMID>21730309</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>March 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Jan Larmann</investigator_full_name>
    <investigator_title>Dr., PhD</investigator_title>
  </responsible_party>
  <keyword>Presepsin</keyword>
  <keyword>sCD14-ST</keyword>
  <keyword>biomarker</keyword>
  <keyword>perioperative risk</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

